Engineered red blood cells could carry precious therapeutic cargo

June 30, 2014, Whitehead Institute for Biomedical Research
blood cells
Scanning electron micrograph of blood cells. From left to right: human erythrocyte, thrombocyte (platelet), leukocyte. Credit: public domain

Whitehead Institute scientists have genetically and enzymatically modified red blood cells to carry a range of valuable payloads—from drugs, to vaccines, to imaging agents—for delivery to specific sites throughout the body.

"We wanted to create high-value red cells that do more than simply carry oxygen," says Whitehead Founding Member Harvey Lodish, who collaborated with Whitehead Member Hidde Ploegh in this pursuit. "Here we've laid out the technology to make mouse and human in culture that can express what we want and potentially be used for therapeutic or diagnostic purposes."

The work, published this week in the Proceedings of the National Academy of Sciences (PNAS), combines Lodish's expertise in the biology of red (RBCs) with biochemical methods developed in Ploegh's lab.

RBCs are an attractive vehicle for potential therapeutic applications for a variety of reasons, including their abundance—they are more numerous than any other cell type in the body—and their long lifespan (up to 120 days in circulation). Perhaps most importantly, during RBC production, the that eventually mature to become RBCs jettison their nuclei and all DNA therein. Without a nucleus, a mature RBC lacks any genetic material or any signs of earlier genetic manipulation that could result in tumor formation or other adverse effects.

Exploiting this characteristic, Lodish and his lab introduced genes coding for specific slightly modified normal red cell surface proteins into early-stage RBC progenitors. As the RBCs approach maturity and enucleate, the proteins remain on the cell surface, where they are modified by Ploegh's protein-labeling technique. Referred to as "sortagging," the approach relies on the bacterial enzyme sortase A to establish a strong chemical bond between the surface protein and a substance of choice, be it a small-molecule therapeutic or an antibody capable of binding a toxin. The modifications leave the cells and their surfaces unharmed.

"Because the modified can circulate in the body for up to four months, one could envision a scenario in which the cells are used to introduce antibodies that neutralize a toxin," says Ploegh. "The result would be long-lasting reserves of antitoxin antibodies."

The approach has captured the attention of the U.S. military and its Defense Advanced Research Projects Agency (DARPA), which is supporting the research at Whitehead in the interest of developing treatments or vaccines effective against biological weapons.

Lodish believes the applications are potentially vast and may include RBCs modified to bind and remove bad cholesterol from the bloodstream, carry clot-busting proteins to treat ischemic strokes or deep-vein thrombosis, or deliver anti-inflammatory antibodies to alleviate chronic inflammation. Further, Ploegh notes there is evidence to suggest that modified RBCs could be used to suppress the unwanted immune response that often accompanies treatment with protein-based therapies. Ploegh is exploring whether these RBCs could be used to prime the immune system to allow patients to better tolerate treatment with such therapies.

Explore further: Modified antibodies trigger immune response, point to novel vaccine design strategies

More information: Engineered red blood cells as carriers for systemic delivery of a wide array of functional probes, PNAS, June 30, 2014. www.pnas.org/cgi/doi/10.1073/pnas.1409861111

Related Stories

Modified antibodies trigger immune response, point to novel vaccine design strategies

January 7, 2013
In an approach with the potential to aid therapeutic vaccine development, Whitehead Institute scientists have shown that enzymatically modified antibodies can be used to generate highly targeted, potent responses from cells ...

Protein found to regulate red blood cell size and number

August 28, 2012
The adult human circulatory system contains between 20 and 30 trillion red blood cells (RBCs), the precise size and number of which can vary from person to person. Some people may have fewer, but larger RBCs, while others ...

Flu virus wipes out immune system's first responders to establish infection

October 20, 2013
Revealing influenza's truly insidious nature, Whitehead Institute scientists have discovered that the virus is able to infect its host by first killing off the cells of the immune system that are actually best equipped to ...

Pursuit of scalable, on-demand blood for transfusions could yield novel means of therapeutics delivery

November 18, 2013
Red blood cells are the most transfused blood product in battlefield trauma care. Unfortunately, they are sometimes in limited supply in a battlefield environment. DARPA created its Blood Pharming program to potentially relieve ...

Keeping up with demand for red blood cells

July 16, 2012
(Medical Xpress) -- Two cellular proteins team up to provide a steady supply of red blood cells (RBCs), according to a study by Lizhao Wu, PhD, of the University of Medicine and Dentistry of New Jersey-New Jersey Medical ...

AAP still opposes retail-based clinics for pediatric primary care

February 24, 2014
(HealthDay)—The American Academy of Pediatrics (AAP) continues to oppose retail-based clinics (RBCs) as a source of pediatric primary care, according to a policy statement published online Feb. 24 in Pediatrics.

Recommended for you

Scientists solve the case of the missing subplate, with wide implications for brain science

June 21, 2018
The disappearance of an entire brain region should be cause for concern. Yet, for decades scientists have calmly maintained that one brain area, the subplate, simply vanishes during the course of human development. Recently, ...

LincRNAs identified in human fat tissue

June 21, 2018
A large team of researchers from the U.S. and China has succeeded in identifying a number of RNA fragments found in human fat tissue. In their paper published in the journal Science Translational Medicine the group describes ...

Key molecule of aging discovered

June 21, 2018
Every cell and every organism ages sooner or later. But why is this so? Scientists at the German Cancer Research Center in Heidelberg have now discovered for the first time a protein that represents a central switching point ...

Compound made inside human body stops viruses from replicating

June 20, 2018
The newest antiviral drugs could take advantage of a compound made not by humans, but inside them. A team of researchers has identified the mode of action of viperin, a naturally occurring enzyme in humans and other mammals ...

Research reveals zero proof probiotics can ease your anxiety

June 20, 2018
If you're expecting probiotics to reduce your anxiety, it might be time to put down that yogurt spoon—or supplement bottle—and call a professional instead.

Long-term estrogen therapy changes microbial activity in the gut, study finds

June 20, 2018
Long-term therapy with estrogen and bazedoxifene alters the microbial composition and activity in the gut, affecting how estrogen is metabolized, a new study in mice found.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.